Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways

CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought

(2018) Mary E. Klein et al.   CANCER CELL

Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies

(2018) Dorota Kwapisz   Breast Cancer

Maftools: efficient and comprehensive analysis of somatic variants in cancer

(2018) Anand Mayakonda et al.   GENOME RESEARCH

Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma

(2017) A Dispenzieri et al.   LEUKEMIA

The non-canonical poly(A) polymerase FAM46C acts as an onco-suppressor in multiple myeloma

(2017) Seweryn Mroczek et al.   Nature Communications

Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker

(2017) S S Chavan et al.   Blood Cancer Journal

Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma

(2016) N. Weinhold et al.   BLOOD

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

(2016) P. Sonneveld et al.   BLOOD

The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma

(2016) C. Pawlyn et al.   CLINICAL CANCER RESEARCH

ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization

(2016) Guangchuang Yu et al.   Molecular BioSystems

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

(2016) András Kotschy et al.   NATURE

Genomic complexity of multiple myeloma and its clinical implications

(2016) Salomon Manier et al.   Nature Reviews Clinical Oncology

A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma

(2016) N Bolli et al.   Blood Cancer Journal

Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature

(2016) Marta Lionetti et al.   Oncotarget

Compendium ofFAM46Cgene mutations in plasma cell dyscrasias

(2015) Marzia Barbieri et al.   BRITISH JOURNAL OF HAEMATOLOGY

A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines

(2015) Sophie Maïga et al.   CYTOMETRY PART A

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma

(2015) Brian A. Walker et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma

(2015) Ruben Niesvizky et al.   LEUKEMIA & LYMPHOMA

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

(2015) J D Leverson et al.   Cell Death & Disease

Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes

(2015) Moritz Gerstung et al.   Nature Communications

Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation

(2015) Marta Lionetti et al.   Oncotarget

Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma

(2015) Charlotte Kervoëlen et al.   Oncotarget

Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns

(2015) Ingrid Cifola et al.   Oncotarget

PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance

(2014) B. Tessoulin et al.   BLOOD

RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53 abnormal myeloma cells independently of the p53 pathway

(2014) Sylvanie Surget et al.   BMC CANCER

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

(2014) Jens G. Lohr et al.   CANCER CELL

Combination of International Scoring System 3, High Lactate Dehydrogenase, and t(4;14) and/or del(17p) Identifies Patients With Multiple Myeloma (MM) Treated With Front-Line Autologous Stem-Cell Transplantation at High Risk of Early MM Progression–Related Death

(2014) Philippe Moreau et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity

(2014) Zhi-Fu Tao et al.   ACS Medicinal Chemistry Letters

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma

(2013) C Touzeau et al.   LEUKEMIA

Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other

(2013) Sylvanie Surget et al.   LEUKEMIA & LYMPHOMA

A high-performance computing toolset for relatedness and principal component analysis of SNP data

(2012) X. Zheng et al.   BIOINFORMATICS

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

(2012) J. P. Leonard et al.   BLOOD

Cell Death via DR5, but not DR4, Is Regulated by p53 in Myeloma Cells

(2012) S. Surget et al.   CANCER RESEARCH

clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters

(2012) Guangchuang Yu et al.   OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY

ABT-737 is highly effective against molecular subgroups of multiple myeloma

(2011) L. Bodet et al.   BLOOD

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Initial genome sequencing and analysis of multiple myeloma

(2011) Michael A. Chapman et al.   NATURE

A diverse range of gene products are effectors of the type I interferon antiviral response

(2011) John W. Schoggins et al.   NATURE

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines

(2010) J. Moreaux et al.   HAEMATOLOGICA